Interstitial Lung Disease: The ACR/CHEST ILD Guidelines in Practice

New Guidelines on the Screening, Monitoring, and Treatment of Interstitial Lung Disease Secondary to Systemic Autoimmune Rheumatic Diseases

In collaboration with the American College of Chest Physicians, the American College of Rheumatology has released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). These guidelines are designed to assist clinicians in the rapid diagnosis and optimal management of these complex conditions, ensuring better patient outcomes.

Target Audience: This webinar is intended for healthcare professionals, including rheumatologists, pulmonologists, internists, and other clinicians involved in the care of adult patients with systemic autoimmune rheumatic diseases.

Special Focus: The guidelines include recommendations for the management of rapidly progressing ILD, a severe and rare manifestation most commonly associated with idiopathic inflammatory myopathy.

Learning Objectives: By attending this webinar, participants will be able to:

• Understand the guideline development process including scope of the guidelines, the GRADE process for evaluating evidence, involvement of patients in the guideline development, use of surrogate outcomes, addressing low certainty evidence, and the role and decisions of the voting panel
• Understand the new guidelines for the screening and monitoring of ILD in patients with systemic autoimmune rheumatic diseases.
• Identify the key diagnostic criteria and tools for early detection of ILD in the context of SARDs.
• Implement evidence-based treatment strategies for managing ILD in patients with systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, rheumatoid arthritis, and Sjögren’s disease.
• Recognize the clinical features and recommended management approaches for rapidly progressing ILD in patients with idiopathic inflammatory myopathy.
• Integrate multidisciplinary approaches to optimize patient care and improve outcomes for those with ILD secondary to SARDs.